Switch Therapeutics
Aiden Aceves, Ph.D., currently serves as a Board Observer at 858 Therapeutics, Superluminal Medicines Inc., Profluent Bio, Capacity Bio, DEM Biopharma, Inc., and Switch Therapeutics, while holding the position of Board Director at Basking Biosciences Inc., Cirsium Biosciences, and Stealth RNA Biotech Company. With a Doctor of Philosophy in Bioengineering from Caltech, obtained from 2017 to 2021, and a Bachelor's Degree in Chemistry from the University of California, Riverside, Aiden Aceves combines advanced education with extensive experience in biopharmaceutical board governance.
This person is not in any teams
This person is not in any offices
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.